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Anemia in Children With Cancer Is Associated With Decreased Erythropoietic
Activity and Not With Inadequate Erythropoietin Production
By Francis Corazza, Yves Beguin, Pierre Bergmann, Marie Andre´, Alina Ferster, Christine Devalck,
Pierre Fondu, Marc Buyse, and Eric Sariban
A defect in erythropoietin (EPO) production has been advo-
cated as being the main cause of anemia presented at time of
diagnosis or during treatment by adults with solid tumors.
On the basis of this defect, anemic cancer patients, both
adults and children, have been treated with recombinant
human EPO (rHuEPO). To further elucidate the pathophysiol-
ogy of anemia in children with cancer, we measured serum
soluble transferrin receptor (sTfR), a quantitative marker of
erythropoiesis, and serum EPO at time of diagnosis and
during chemotherapy in children suffering from solid tumor
or leukemia. We determined serum EPO in 111 children (55
leukemia, 56 solid tumors) at time of diagnosis. In the last 44
patients (23 leukemia and 21 solid tumors), sTfR levels were
also measured. Serum EPO together with sTfR levels were
also determined in 60 children receiving chemotherapy (29
leukemia, 31 solid tumors). These results were compared
with those obtained from appropriate control groups. In all
patients, we found a highly significant correlation between
the logarithm of EPO (log[EPO]) and the hemoglobin (Hb)
level. In all subsets of patients, sTfR levels were inappropri-
ately low for the degree of anemia. Neither leukemic nor
solid tumor groups showed a significant inverse relationship
between log(sTfR) and the Hb level as would be expected in
anemic patients with appropriate marrow response. Thus, in
children with cancer, anemia is associated with a decreased
total bone marrow erythropoietic activity which, in contrast
to what has been reported in anemic cancer adults, is not
related to defective EPO production.
r 1998 by The American Society of Hematology.
THE LEVEL OF BONE MARROW erythropoietic activitydepends on the number of erythroid precursors involved
in proliferation and differentiation. In the human body, 80% of
the transferrin receptors are located in the erythroid marrow.
Because a constant relationship exists between membrane
receptors and serum receptors, determination of serum soluble
transferrin receptors (sTfR) has been used to assess bone
marrow erythropoietic activity.1 The late stages of erythropoi-
esis are mainly dependent on erythropoietin (EPO), which
induces proliferation and terminal differentiation of committed
red blood cell progenitors. In the presence of a normal marrow
stem cell reserve, erythropoiesis increases in proportion to the
degree of anemia through an exponential increase of EPO.
Thus, simultaneous determination of sTfR levels (erythroid
marrow activity) and serum EPO levels (erythropoietin stimula-
tion) has been used to investigate the pathophysiology of red
blood cell disorders in different clinical settings.
Several studies of patients with hematologic malignancies
have described EPO levels appropriate for the degree of
anemia.2-4 In contrast, in patients suffering from solid malignan-
cies, the observed defect in EPO production has been advocated
as being the main cause of anemia presented by these patients
either at time of diagnosis or during treatment.5 This defect has
been put forward as a rational basis for treating the anemia of
cancer patients, both adults and children, with recombinant
human EPO (rHuEPO).
In the present study, we investigated the pathophysiology of
anemia presented at time of diagnosis and during treatment by
children suffering from either solid tumors or hematologic
malignancies. The adequacy of EPO secretion in response to
anemia and the total erythropoietic activity was assessed by
determination of serum EPO and sTfR levels, respectively. Our
data indicate that the anemia presented by children with cancer
is due to defective erythroid progenitor proliferation and not to
inappropriate EPO secretion.
MATERIALS AND METHODS
Patient and control populations. We determined serum EPO level
at time of diagnosis in 111 children admitted for leukemia (n 5 55) or a
solid tumor (n 5 56). Diagnoses were: acute lymphoblastic leukemia
(50), acute myeloid leukemia (5), neuroblastoma (13), brain tumor (10),
nephroblastoma (9), soft tissue sarcoma (6), non-Hodgkin’s lymphoma
(5), osteosarcoma (4), germinal tumor (4), Hodgkin’s disease (3), and
primitive neuroectodermic tumor (2). Among the 56 patients with a
solid tumor, 6 had bone marrow involvement by malignant cells. There
were 73 boys and 38 girls. The mean age was 5.5 6 3.2 years (range, 1
to 15) in the leukemic group and 6.3 6 4.8 years (range, 0.2 to 17) in the
group with solid tumors. Blood samples at time of diagnosis were
obtained before any treatment or transfusion. The sera were kept frozen
until EPO measurement. Hemoglobin (Hb), serum creatinine, and
serum albumin levels were measured concurrently. Levels of serum
sTfR were also measured in the last 44 patients, 23 with leukemia and
19 with a solid tumor (including 2 with bone marrow involvement).
These 44 patients were white, except for 1 African subject. The study
was approved by the institutional review board.
Among the 111 patients, 88 (51 with leukemia and 37 with a solid
tumor) were considered anemic as defined by an Hb level more than two
standard deviation (SD) below the normal mean value for age.6 No
patient had hypoxemia. One patient with acute myeloid leukemia was
excluded because of concomitant acute renal failure; all other patients
had normal renal function.
We determined serum EPO together with sTfR in 60 chemotherapy-
treated children including 29 leukemic and 31 solid tumor patients. The
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median duration of chemotherapy at time of study was 2 months (range,
1 to 4) for the leukemic group and 4 months (range, 1 to 11) for the solid
tumor group. All leukemic patients were in complete remission as
assessed by bone marrow microscopic evaluation. Among the 31 solid
tumor patients, 6 had been exposed to cisplatin for a median time of 3
months (range, 1 to 6).
In leukemic patients, serum EPO and sTfR were also measured later
during the treatment: at the end of intensive treatment (n 5 24, median
duration of treatment, 4.5 months; range, 4 to 6) and during mainte-
nance chemotherapy (n 5 15, median time of treatment, 9 months;
range, 7 to 12).
The reference EPO curve was constructed using data obtained in 23
children, 17 boys and 6 girls, with iron deficiency anemia (17) or sickle
cell disease (6), two conditions where EPO production has been shown
to be appropriate to the degree of anemia.5,7 Control children had
normal renal function (creatinine: 0.5 6 0.17 mg/dL), no inflammation,
and a good nutritional status (observed/optimal weight ratio: 92.3 6 13;
serum albumin: 4.3 6 0.4 g/dL).
Patients with erythroid hypoplasia have been reported to have a
higher EPO production in response to anemia as compared with patients
with nonhypoplastic anemia.8 Accordingly, to compare leukemic pa-
tients with control patients with a similar erythroid hypoplasia, we
determined serum EPO levels in 10 anemic patients with aplastic
anemia (n 5 9) or Blackfan-Diamond anemia (n 5 1). The mean age in
this group was 11 6 7 years (range, 1 to 18).
To construct the reference sTfR curve evaluating the erythropoietic
response to anemia, samples were obtained from 18 patients with
hemolytic anemia and 18 with dyserythropoietic anemia. Patients with
iron deficiency were excluded, as sTfR levels are inappropriately
increased in this condition.9
EPO and sTfR immunoassays. Immunoreactive EPO levels were
measured by a commercially available immunoradiometric assay (125I-
EPO Coat RIA, Bio-Me´rieux, Marcy L’Etoile, Lyon, France) that uses
two different monoclonal antibodies raised against different epitopes of
rHuEPO. The range of normal values in 26 nonanemic healthy adults
was 0.9 to 8.5 mU/mL (mean 6 SD, 4.7 6 1.9).10 The interassay
coefficient of variation ranged from 4% to 12% when EPO concentra-
tion was 40 and 4 mU/mL, respectively. There was no influence of sex
or age on the results.
An enzyme-linked immunosorbent assay based on TfR polyclonal
antibodies was used to measure sTfR as previously published.1 Each
sample was run in triplicate. The interassay coefficient of variation was
7.2%. With this assay, mean sTfR in 150 iron replete normal subjects
was 5,000 6 1,050 µg/L (mean 6 SD). There was no influence of sex or
age on the results.
Hemoglobin levels were determined using Bayer H2 or H3 auto-
mated hematology analyzers (Bayer Diagnostics, Tarrytown, NY). The
other biologic parameters were measured by standard laboratory
methods.
Statistical analysis. Differences between groups for mean biologic
values were tested for statistical significance using the Student’s t-test.
The correlation coefficients between log(EPO) or log(sTfR) and Hb
levels were computed in least squares regression equations. The slopes
and y-intercepts of the regression lines were tested for equality between
groups by Student’s t-test. Furthermore, the adequacy of EPO and sTfR
levels in relation to the degree of anemia was evaluated individually by
computing the ratio between the logarithm of the observed value and the
logarithm of the expected result [O/E log(EPO) or log(sTfR) ratios]
according to the regression line constructed with the control group. The
homogeneity of variance for these parameters among the various groups
was tested by F test. All biologic values are reported as mean 6 SD.
RESULTS
Adequate EPO response at diagnosis in anemic children
suffering from leukemia or solid tumor. Serum proteins,
albumin, and creatinine levels in patients at diagnosis were
normal and not different from those in the control group. The
mean Hb level was not significantly different in patients with
malignancy as compared with control anemic patients. Mean
EPO level was similar in leukemic patients and in patients with
solid tumors as compared with control group. When log(EPO)
was plotted as a function of Hb, a significant inverse linear
relationship was found (Fig 1A and C) with equivalent coeffi-
cient of correlation in the leukemic, solid tumor, and control
groups (Table 1). The slope and the y-intercept of the three
regression lines was not significantly different. Most patients
(73% of patients with leukemia and 86% of those with solid
tumors) fell within 95% confidence intervals of control sub-
jects; in only 5% (3 of 55) of leukemic patients and 14% (8 of
56) of patients with solid tumor was a blunted EPO response
observed (Fig 1A and C). As compared with anemic controls,
the mean O/E log(EPO) ratio was not different in solid tumor
patients and was even significantly elevated in leukemic
patients (Table 1). Variance of this ratio was higher in both
patient groups than in controls. In addition, the equations of the
regression lines for log(EPO), as well as the mean O/E
log(EPO) ratios, were not different when leukemic patients at
time of diagnosis were compared with patients with aplastic
anemia (Table 1).
Decreased erythropoiesis as measured by sTfR levels in
anemic cancer children at time of diagnosis. In both groups of
cancer patients evaluated at time of diagnosis, sTfR levels were
significantly lower than in the control group (3,537 6 2,623
µg/L, 5,923 6 3,044 µg/L and 24,490 6 16,130 µg/L in
leukemic, solid tumor, and control groups, respectively). In
addition, we did not observe the inverse relationship between
sTfR and Hb levels that was obtained in control anemic subjects
with adequate marrow function (Fig 2A and C). The regression
equations for the leukemic and solid tumor groups were
respectively: log(sTfR) 5 3.454 1 (0.004 Hb), r 5 .04, P .
.05; and log(sTfR) 5 4.097 2 (0.035 Hb), r 5 2.379, P . .05.
Solid tumor patients with (n 5 2) or without (n 5 19) bone
marrow infiltration had similar sTfR/Hb relationships. Eighty-
seven percent of leukemic patients and 48% of solid tumor
patients had sTfR values well below the expected range
computed from the control group; therefore, the O/E log(sTfR)
ratios were significantly reduced in both groups of patients as
compared with controls (0.42 6 0.13, 0.86 6 0.06, and 1.00 6
0.04 in leukemic, solid tumor, and control groups, respectively).
Adequate EPO response in anemic cancer children exposed
to chemotherapy. To explore whether the pathophysiology of
anemia observed during treatment was similar to the one
observed at time of diagnosis, EPO and sTfR measurements
were performed in patients treated by intensive chemotherapy.
Both in leukemic and solid tumor patients, the inverse relation-
ship between log(EPO) and Hb was conserved and was not
different from the one observed at time of diagnosis or in the
control group (Fig 1B and D and Table 1). In addition, leukemic
patients all along their treatment retained an adequate EPO
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response to the degree of anemia as indicated by O/E log(EPO)
ratio values close to 1 except in the early phase of intensive
chemotherapy where this ratio was even elevated (Table 1). No
leukemic patients presented a blunted EPO response as defined
by an EPO level below the lower limit of the 95% confidence
interval of the control group (Fig 1B). Only 3 of 25 patients with
solid tumors not exposed to cisplatin did present a blunted EPO
response (Fig 1D); the 6 patients treated by cisplatin had a
significant lower O/E log(EPO) ratio as compared with the
other patients (Table 1).
Decreased erythropoiesis in anemic cancer children exposed
to chemotherapy. In most treated patients (90% of leukemic
patients and 69% of patients with solid tumors), erythropoietic
activity as assessed by sTfR level was inappropriately low for
the degree of anemia (Fig 2B and D). Solid tumor patients did
not show the expected inverse relationship between sTfR and
Fig 1. Relation of the serum
EPO to Hb levels in patients with
leukemia studied at time of diag-
nosis, n 5 55 (A) or during inten-
sive chemotherapy (CT), n 5 29
(B) and in patients with solid
tumor at diagnosis, n 5 56 (C), or
during intensive CT, n 5 31 (D).
Solid lines represent the regres-
sion lines computed in each
group of patients. Dashed lines
depict the regression line and
the 95% confidence limits of the
control group. In graph (D), solid
triangles represent patients re-
ceiving cisplatin (n 5 6).
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Hb: log(sTfR) 5 3.329 1 (0.026 Hb), r 5 .217, P . .05 (Fig
2D). In leukemic patients, there was even a positive correlation
between sTfR and Hb: log(sTfR) 5 2.649 1 (0.084 Hb), r 5
.602, P , .008 (Fig 2B). Altogether, these results indicate that
the anemia was associated with a lack of erythropoietic
progenitors and not with EPO deficiency.
DISCUSSION
The EPO response to anemia in patients with cancer has been
a matter of debate. Among adults with solid tumors, inadequate
EPO response to the anemia has been reported in patients at
time of diagnosis or during treatment,5,11 but this has not been a
constant finding.12,13 An EPO defect has been well documented
in patients with multiple myeloma, even in the absence of renal
failure.14 However, in other hematologic malignancies, includ-
ing chronic lymphocytic leukemia,4 Hodgkin’s disease,3 and
acute leukemia,2 most of the patients showed an adequate EPO
response to anemia.
Whether these findings in adults also apply to children has
not been well-demonstrated. In the present study, a significant
inverse relationship between log(EPO) and Hb was observed,
either at time of diagnosis or during chemotherapy, in children
suffering from leukemia or solid tumors. In only 10% (11 of
111) of newly diagnosed cancer patients and 5% (3 of 54) of
treated patients not exposed to cisplatin was a blunted EPO
response observed. Individual EPO response to anemia, ana-
lyzed by computing the ratio between observed and expected
log(EPO), was also appropriate. Similar results were found
when leukemic patients at time of diagnosis were compared
with patients with erythroid hypoplasia secondary to aplastic
anemia, a group of patients known to have the highest EPO
levels in response to anemia.8 Altogether, these results suggest
that, in marked contrast to what has been observed in adults,5
EPO production in response to anemia is undamaged in most
children with malignancy-associated anemia.
Leukemic patients evaluated had massive blastic infiltration
of the bone marrow explaining the absence of erythroid
proliferation. In contrast, most children with solid tumors
presented without bone marrow metastases. However, both
populations presented erythroid hypoplastic marrow as indi-
cated by low sTfR levels; thus, it is possible that the defect in
erythroid progenitor activity observed in these patients is
secondary to the presence of soluble inhibitory factors associ-
ated with malignancy.
Increased production of several cytokines, including interleu-
kin-1 (IL-1),15 tumor necrosis factor-a (TNF-a),16 interferon-g
(IFN-g),17 and transforming growth factor-b (TGF-b)18 has
been demonstrated in a variety of cancers. These cytokines
affect erythropoiesis through different pathways.19 In vitro, they
inhibit the growth of erythropoietic progenitors, decrease the
sensitivity of erythropoietic cells to the trophic effect of EPO,
and suppress the hypoxia-dependent EPO production.20-22 In
vivo, these cytokines have also been reported to suppress
erythropoiesis.23-25 In addition, hematopoietically active chemo-
kines such as macrophage inflammatory protein-1a have been
involved in the inhibition of erythropoiesis both in vitro26 and in
vivo.27 It remains to be determined if one or more of these
factors are involved in the etiology of cancer-associated anemia.
In contrast to results published in adults,5 EPO response in
children under treatment for leukemia or a solid tumor was also
adequate for the degree of anemia except in those patients
receiving cisplatin. This suggests that the anemia presented by
these children was mainly due to the direct myelotoxic effect of
chemotherapy and that inadequate EPO response plays a very
minor role, if any, in the etiology of the anemia.
Treatment with rHuEPO has been partially effective in the
treatment of the anemia of cancer patients receiving or not
receiving chemotherapy.28,29 However, only a minority of the
patients show a complete response, and the doses required are
considerably larger than those used in renal failure patients. In
contrast to this latter population, many cancer patients fail to
respond to high doses of rHuEPO. Although algorithms have
been proposed, there is no convenient and reliable predictor of
response to rHuEPO in adults.30 The small studies conducted in
children with solid tumors show a minor effectiveness of
rHuEPO with only a small reduction in transfusion needs.31,32
Although rHuEPO use has not been associated with important
toxicity in adult cancer patients, the risks of rHuEPO treatment
in children has yet to be defined.
In conclusion, our data indicate that the mechanisms of

















Controls (23) 9.1 6 1.5 log(EPO) 5 3.48 2 0.20 Hb 20.73 ,.001 1.00 6 0.18 —
Aplastic anemia (10) 7.4 6 1.4 log(EPO) 5 5.05 2 0.33 Hb 20.73 ,.01 1.33 6 0.23 ,.001
Leukemic patients
At diagnosis (55) 8.6 6 2.2 log(EPO) 5 3.74 2 0.20 Hb 20.63 ,.001 1.21 6 0.33 ,.0001
During CT, early (29) 2 (1-4) 8.9 6 1.6 log(EPO) 5 4.80 2 0.32 Hb 20.78 ,.001 1.22 6 0.29 ,.01
During CT, late (24) 5 (4-6) 10.2 6 1.9 log(EPO) 5 4.25 2 0.27 Hb 20.74 ,.001 1.07 6 0.37 NS
Maintenance CT (15) 9 (7-12) 11.3 6 1.0 log(EPO) 5 2.72 2 0.13 Hb 20.33 ,.01 1.10 6 0.30 NS
Solid tumor patients
At diagnosis (56) 10.7 6 2.2 log(EPO) 5 3.32 2 0.21 Hb 20.70 ,.001 0.90 6 0.47 NS
During CT (31) 4 (1-11) 10.3 6 1.6 log(EPO) 5 2.72 2 0.15 Hb 20.47 ,.001 0.89 6 0.37 NS
CT with cisplatin (6) 3 (1-6) 10.6 6 0.6 log(EPO) 5 2.28 2 0.13 Hb 20.37 ,.01 0.70 6 0.15 ,.05
Abbreviations: CT, chemotherapy; NS, not significant.
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cancer anemia in children differ from the ones reported in
adults. In our study, anemia was associated with early defective
erythropoiesis and not with inadequate EPO production. Thus,
treatment of anemic cancer children with rHuEPO might be of
limited efficacy because mechanisms others than a defective
EPO response negatively control marrow erythropoietic activ-
ity. Administration of growth factors known to promote the
growth of more primitive cells might be of interest. In addition,
agents such as antiinflammatory compounds33 and monoclonal
antibodies capable of reversing the effects of inhibitory cyto-
kines might also be of potential clinical use.
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Fig 2. Relation of serum sTfR
to Hb levels in patients with leu-
kemia studied at time of diagno-
sis, n 5 21 (A) or during intensive
CT, n 5 23 (B) and in patients
with solid tumor at diagnosis,
n 5 21 (C), or during intensive
CT, n 5 30 (D). Solid lines repre-
sent the regression lines com-
puted in each group of patients.
Dashed lines depict the regres-
sion line and the 95% confidence
limits of the control population
showing an appropriate stimula-
tion of erythropoiesis by the ane-
mia.
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